TBTiziana Bruno

Tiziana Bruno

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tiziana Bruno has a total of 24 co-authors. Here are the top co-authors by number of shared publications:

  • Giacomo Corleone

    Department of Surgery and Cancer, The Imperial Centre for Translational and Experimental Medicine, Imperial College London, London, UK

    2 shared publications
  • Maria Chiara Cappelletto

    Gene Expression and Cancer Models Laboratory, Translational Research Area, IRCCS Regina Elena National Cancer Institute

    2 shared publications
  • Andrea Mengarelli

    Hematology and Stem Cell Transplant Unit IRCCS Regina Elena National Cancer Institute Rome Italy

    1 shared publication
  • Belinda Palermo

    Unit of Tumor Immunology and Immunotherapy, Department of Research, Advanced Diagnostics and Technological Innovation, IRCCS Regina Elena National Cancer Institute, Rome, Italy

    1 shared publication
  • Bruno Amadio

    Gene Expression and Cancer Models Unit, Department of Research and Advanced Technologies Translational Research Area, IRCCS Regina Elena National Cancer Institute, Rome, Italy

    1 shared publication
  • Clelia Cortile

    Gene Expression and Cancer Models Unit, Department of Research and Advanced Technologies Translational Research Area, IRCCS Regina Elena National Cancer Institute, Rome, Italy

    1 shared publication

Latest Publications

  • Open Access

    Epigenomic profiling of H3K27ac in a primary patient-derived multiple myeloma cell line using two different low-input methods with concordant results

    by Maria Chiara Cappelletto, Giacomo Corleone, Francesca De Nicola, Tiziana Bruno

    Dysregulation of epigenetic and genetic mechanisms driving malignant transformation is a hallmark of cancer [1]. In multiple myeloma (MM), a plasma cell malignancy characterized by clonal expansion...

  • Open Access

    Nuclear respiratory factor 1 promotes cell survival in multiple myeloma under proteasome inhibition therapy

    by Tiziana Bruno, Maria Chiara Cappelletto, Clelia Cortile, Stefano Di Giovenale, Bruno Amadio, Francesca De Nicola, Italia Falcone, Stefano Giuliani, Belinda Palermo, Valeria Catena, et al.

    Multiple myeloma (MM) continues to be an incurable malignancy, even with recent therapeutic advancements. Although epigenetic dysregulation at cis-regulatory elements is known to drive disease progression, the complete molecular mechanisms underlying these alterations are poorly understood. Using Assay for Transposase-Accessible Chromatin with high-throughput sequencing analysis combined with the computational footprinting of CD138+ cells from 55 patients with MM, we depicted the dynamic changes in chromatin accessibility during disease progression and identified nuclear respiratory factor 1 (NRF1) as a master regulator of vital MM survival pathways. We demonstrated that NRF1 maintains proteasome homeostasis by orchestrating the ubiquitination pathway, which is essential for MM cell survival. We discovered a novel enhancer element that physically interacts with the NRF1 promoter, sustaining its expression. Targeting this enhancer RNA reduced NRF1 levels and increased tumor cell sensitivity to bortezomib (BTZ), suggesting therapeutic potential. In xenograft models, we showed that antisense oligonucleotides targeting the NRF1 enhancer, either alone or combined with BTZ, significantly decreased tumor burden and improved survival. Our findings reveal a previously unknown NRF1-dependent mechanism regulating MM cell survival and present a promising therapeutic approach through the manipulation of its regulatory network.